Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
7 June 2019
Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.
Professor Nancy Devlin appointed as OHE Senior Visiting Fellow
22 May 2019
Professor Nancy Devlin has recently been awarded an honorary position at OHE as a Senior Visiting Fellow.
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
Market-Driven, Value-Based Advanced Commitment (MVAC) is a new mechanism to help re-direct private-sector R&D investments where they’re needed most. We propose to use MVAC to encourage…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
OHE at ISPOR 2019
8 May 2019
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans, 18-22 May.
The Value of International Volunteers’ Experience to the NHS
24 April 2019
A new paper by OHE and Health Education England on the value of international volunteers’ experience to the NHS has been published in Globalization and Heath.
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
Transparency as a principle of good governance is not the same as transparency for improving access by lowering prices. In fact, the former often carries an…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
Report does not recommend price transparency for on-patent medicines, but buyers should share multi-source product price data among themselves. Transparency of the procurement process encourages bidders.…